Open this publication in new window or tab >>AstraZeneca, R&D, Data Sci & Quantitat Biol, Discovery Sci, Gothenburg, Sweden..
Translat Genom Ctr Genom Res, Discovery Sci, R&D, Translat Genom,Ctr Genom Res, Gothenburg, Sweden..
Translat Sci & Expt Med, Res & Early Dev Cardiovasc Renal & Metab CVRM, BioPharmaceut R&D, AstraZeneca, Gothenburg, Sweden..
Karolinska Inst, Dept Med Huddinge, Campus Flemingsberg, S-14157 Huddinge, Sweden..
Neurosci, BioPharmaceut R&D, AstraZeneca, Cambridge, England..
Neurosci, BioPharmaceut R&D, AstraZeneca, Cambridge, England..
Neurosci, BioPharmaceut R&D, AstraZeneca, Cambridge, England..
Neurosci, BioPharmaceut R&D, AstraZeneca, Cambridge, England..
AstraZeneca, R&D, Data Sci & Quantitat Biol, Discovery Sci, Gothenburg, Sweden..
AstraZeneca, R&D, Data Sci & Quantitat Biol, Discovery Sci, Gothenburg, Sweden.;Univ Cambridge, Early Canc Inst, Cambridge, England..
AstraZeneca, R&D, Data Sci & Quantitat Biol, Discovery Sci, Gothenburg, Sweden..
Biosci Renal Res & Early Dev, Cardiovasc Renal & Metab CVRM, BioPharmaceut R&D, AstraZeneca, Gothenburg, Sweden..
Univ Wurzburg, Inst Pharmacol & Toxicol, Wurzburg, Germany.;Georg August Univ Gottingen, Clin Cardiol & Pneumol, Gottingen, Germany.;DZHK German Ctr Cardiovasc Res, Partner Site Gottingen, Gottingen, Germany.;Univ Clin Wurzburg, Comprehens Heart Failure Ctr CHFC, Dept Translat Res, Wurzburg, Germany..
Univ Clin Wurzburg, Comprehens Heart Failure Ctr CHFC, Dept Translat Res, Wurzburg, Germany..
Univ Clin Wurzburg, Comprehens Heart Failure Ctr CHFC, Dept Translat Res, Wurzburg, Germany..
Karolinska Inst, Dept Med, Stockholm, Sweden.;Karolinska Univ Hosp, Dept Cardiol, Stockholm, Sweden..
Univ Clin Wurzburg, Comprehens Heart Failure Ctr CHFC, Dept Translat Res, Wurzburg, Germany..
Karolinska Inst, Dept Med Biochem & Biophys, Div Chem 1, Stockholm, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology. Karolinska Inst, Dept Med Huddinge, Campus Flemingsberg, S-14157 Huddinge, Sweden.
Show others...
2024 (English)In: Nature Communications, E-ISSN 2041-1723, Vol. 15, no 1, article id 2358Article in journal (Refereed) Published
Abstract [en]
While excessive production of reactive oxygen species (ROS) is a characteristic hallmark of numerous diseases, clinical approaches that ameliorate oxidative stress have been unsuccessful. Here, utilizing multi-omics, we demonstrate that in cardiomyocytes, mitochondrial isocitrate dehydrogenase (IDH2) constitutes a major antioxidative defense mechanism. Paradoxically reduced expression of IDH2 associated with ventricular eccentric hypertrophy is counterbalanced by an increase in the enzyme activity. We unveil redox-dependent sex dimorphism, and extensive mutual regulation of the antioxidative activities of IDH2 and NRF2 by a feedforward network that involves 2-oxoglutarate and L-2-hydroxyglutarate and mediated in part through unconventional hydroxy-methylation of cytosine residues present in introns. Consequently, conditional targeting of ROS in a murine model of heart failure improves cardiac function in sex- and phenotype-dependent manners. Together, these insights may explain why previous attempts to treat heart failure with antioxidants have been unsuccessful and open new approaches to personalizing and, thereby, improving such treatment.
Place, publisher, year, edition, pages
Springer Nature, 2024
National Category
Physiology and Anatomy
Identifiers
urn:nbn:se:uu:diva-531383 (URN)10.1038/s41467-024-46384-8 (DOI)001191901500027 ()38509128 (PubMedID)
Funder
Swedish Research CouncilKnut and Alice Wallenberg FoundationKarolinska InstituteScience for Life Laboratory, SciLifeLabGerman Research Foundation (DFG)
2024-06-132024-06-132025-02-10Bibliographically approved